Brain endothelial dysfunction in cerebral adrenoleukodystrophy

Brain

Volumn 138, Issue 11, 2015, Pages 3206-3220

  Musolino, Patricia L ^a   Gong, Yi ^a   Snyder, Juliet M T ^a   Jimenez, Sandra ^a   Lok, Josephine ^a   Lo, Eng H ^a   Moser, Ann B ^b   Grabowski, Eric F ^a   Frosch, Matthew P ^a   Eichler, Florian S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

blood brain barrier; demyelination; genetics; leukodystrophy; neurodegeneration; neuroinflammation

Indexed keywords

CELL ADHESION MOLECULE; GELATINASE B; MESSENGER RNA; MYC PROTEIN; TIGHT JUNCTION PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VERY LONG CHAIN FATTY ACID; ABC TRANSPORTER; ABCD1 PROTEIN, HUMAN; AIF1 PROTEIN, HUMAN; CD31 ANTIGEN; CLAUDIN 5; CLDN5 PROTEIN, HUMAN; DNA BINDING PROTEIN; FATTY ACID; ICAM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; MYC PROTEIN, HUMAN; PROTEIN ZO1; TJP1 PROTEIN, HUMAN; VASCULAR CELL ADHESION MOLECULE 1;

ABCD1 GENE; ABCD2 GENE; ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; CAPILLARY ENDOTHELIAL CELL; CELL ADHESION; CEREBRAL ADRENOLEUKODYSTROPHY; CHILD; CONTROLLED STUDY; DEMYELINATION; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOCYTE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION; VERY ELDERLY; YOUNG ADULT; BRAIN; CASE CONTROL STUDY; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; DEMYELINATING DISEASE; ENDOTHELIUM CELL; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METABOLISM; MICROVASCULATURE; MULTIPLE SCLEROSIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CLAUDIN-5; DEMYELINATING DISEASES; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FATTY ACIDS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROZYGOTE; HOMOZYGOTE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICROSCOPY, CONFOCAL; MICROVESSELS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84947712850     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv250     Document Type: Article

References (67)

1. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14: 1142-9.
2. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41: e123-8.
3. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997; 17: 454-64.
4. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002; 16: 2530-43.
5. Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie 2014; 98: 135-42.
6. Berger J, Gartner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006; 1763: 1721-32.
7. Berger J, Pujol A, Aubourg P, Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20: 845-56.
8. Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, et al. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci USA 2012; 109: 15018-23.
9. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003; 100: 10623-8.
10. Cross AH, Dolich S, Raine CS. Antigen processing of myelin basic protein is required prior to recognition by T cells inducing EAE. Cell Immunol 1990; 129: 22-31.
11. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999; 253: 63-77.
12. Droogan AG, McMillan SA, Douglas JP, Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 1996; 64: 185-91.
13. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-93.
14. Eichler F, Mahmood A, Loes D, Bezman L, Lin D, Moser HW, et al. Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy. Arch Neurol 2007; 64: 659-64.
15. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M, et al. Early oxidative damage underlying neurodegeneration in Xadrenoleukodystrophy. Hum Mol Genet 2008; 17: 1762-73.
16. Galea E, Launay N, Portero-Otin M, Ruiz M, Pamplona R, Aubourg P, et al. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta 2012; 1822: 1475-88.
17. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393-407.
18. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000; 123 (Pt 4): 698-709.
19. Holzinger A, Kammerer S, Berger J, Roscher AA. cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 1997; 239: 261-4.
20. Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, Lorey F, et al. Newborn screening for X-linked adrenoleukodystrophy (XALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009; 97: 212-20.
21. Inghirami G, Grignani F, Sternas L, Lombardi L, Knowles DM, Dalla-Favera R. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. Science 1990; 250: 682-6.
22. Kamijo K, Taketani S, Yokota S, Osumi T, Hashimoto T. The 70-kDa peroxisomal membrane protein is a member of the Mdr (Pglycoprotein)-related ATP-binding protein superfamily. J Biol Chem 1990; 265: 4534-40.
23. Law M, Saindane AM, Ge Y, Babb JS, Johnson G, Mannon LJ, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004; 231: 645-52.
24. Loes DJ, Fatemi A, Melhem ER, Gupte N, Bezman L, Moser HW, et al. Analysis of MRI patterns aids prediction of progression in Xlinked adrenoleukodystrophy. Neurology 2003; 61: 369-74.
25. Lombard-Platet G, Savary S, Sarde CO, Mandel JL, Chimini G. A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc Natl Acad Sci USA 1996; 93: 1265-9.
26. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-97.
27. Man S, Ubogu EE, Williams KA, Tucky B, Callahan MK, Ransohoff RM. Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clin Dev Immunol 2008; 2008: 384982.
28. Melhem ER, Loes DJ, Georgiades CS, Raymond GV, Moser HW. Xlinked adrenoleukodystrophy: The role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000; 21: 839-44.
29. Miller DW. Immunobiology of the blood-brain barrier. J Neurovirol 1999; 5: 570-8.
30. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003; 9: 540-9.
31. Moser H, Dubey P, Fatemi A. Progress in X-linked adrenoleukodystrophy. Curr Opin Neurol 2004; 17: 263-9.
32. Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000; 31: 227-39.
33. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361: 726-30.
34. Muneer Z, Wiesinger C, Voigtlander T, Werner HB, Berger J, Forss-Petter S. Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice. PloS One 2014; 9: e108655.
35. Musolino PL, Rapalino O, Caruso P, Caviness VS, Eichler FS. Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy. Brain 2012; 135 (Pt 9): 2676-83.
36. Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, Berger J. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum Mol Genet 1999; 8: 907-13.
37. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013; 19: 1584-96.
38. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12: 154-69.
39. Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011; 14: 1227-35.
40. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-12.
41. Raine CS, Cannella B, Duijvestijn AM, Cross AH. Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Investig 1990; 63: 476-89.
42. Raymond GV, Seidman R, Monteith TS, Kolodny E, Sathe S, Mahmood A, et al. Head trauma can initiate the onset of adrenoleukodystrophy. J Neurol Sci 2010; 290: 70-4.
43. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19: 89-102.
44. Ronaldson PT, Demarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis TP. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metabolism 2009; 29: 1084-98.
45. Rosenberg GA, Dencoff JE, Correa N, Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-32.
46. Rubin LL, Hall DE, Porter S, Barbu K, Cannon C, Horner HC, et al. A cell culture model of the blood-brain barrier. J Cell Biol 1991; 115: 1725-35.
47. Shimizu F, Sano Y, Haruki H, Kanda T. Advanced glycation endproducts induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-beta and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 2011; 54: 1517-26.
48. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Investig 1999; 103: 807-15.
49. Taketomi T, Hara A, Kitazawa N, Takada K, Nakamura H. An adult case of adrenoleukodystrophy with features of olivo-ponto-cerebellar atrophy: II. Lipid biochemical studies. Jpn J Exp Med 1987; 57: 59-70.
50. Theda C, Moser AB, Powers JM, Moser HW. Phospholipids in Xlinked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 1992; 110: 195-204.
51. Thibert KA, Raymond GV, Nascene DR, Miller WP, Tolar J, Orchard PJ, et al. Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction. PloS One 2012; 7: e50430.
52. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 2003; 23: 3937-44.
53. Tossetta G, Paolinelli F, Avellini C, Salvolini E, Ciarmela P, Lorenzi T, et al. IL-1beta and TGF-beta weaken the placental barrier through destruction of tight junctions: an in vivo and in vitro study. Placenta 2014; 35: 509-16.
54. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, et al. CCR1 + /CCR5 + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159: 1701-10.
55. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402-8.
56. van der Voorn JP, Pouwels PJ, Powers JM, Kamphorst W, Martin JJ, Troost D, et al. Correlating quantitative MR imaging with histopathology in X-linked adrenoleukodystrophy. AJNR Am J Neuroradiol 2011; 32: 481-9.
57. Varvel NH, Grathwohl SA, Baumann F, Liebig C, Bosch A, Brawek B, et al. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci USA 2012; 109: 18150-5.
58. Weber FD, Wiesinger C, Forss-Petter S, Regelsberger G, Einwich A, Weber WH, et al. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. Hum Mol Genet 2014; 23: 2542-50.
59. Weinhofer I, Forss-Petter S, Kunze M, Zigman M, Berger J. X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism. FEBS Lett 2005; 579: 5512-6.
60. Wekerle H, Schwab M, Linington C, Meyermann R. Antigen presentation in the peripheral nervous system: Schwann cells present endogenous myelin autoantigens to lymphocytes. Eur J Immunol 1986; 16: 1551-7.
61. Weller M, Liedtke W, Petersen D, Opitz H, Poremba M. Very-lateonset adrenoleukodystrophy: possible precipitation of demyelination by cerebral contusion. Neurology 1992; 42: 367-70.
62. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Investig 2010; 120: 1368-79.
63. Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol 2004; 190: 446-55.
64. Wuerfel J, Bellmann-Strobl J, Brunecker P, Aktas O, McFarland H, Villringer A, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004; 127(Pt 1): 111-9.
65. Yamada T, Ohyagi Y, Shinnoh N, Kikuchi H, Osoegawa M, Ochi H, et al. Therapeutic effects of normal cells on ABCD1 deficient cells in vitro and hematopoietic cell transplantation in the X-ALD mouse model. J Neurol Sci 2004; 218: 91-7.
66. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9: 169-81.
67. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.